clinical trial · NCT07431112
A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
AIRNA Corporation·phase1·recruiting·n = 54
Alpha 1 Antitrypsin DeficiencyAIR-001 SAD dose level 1AIR-001 SAD dose level 2AIR-001 SAD dose level 3AIR-001 SAD dose level 4AIR-001 MD dose level 1AIR-001 MD dose level 2AIR-001 MD dose level 3AIR-001 MD dose level 4
brief summary
This is a Phase 1, open-label, single ascending dose (SAD) and multiple dose (MD) study of AIR-001 in participants with alpha-1 antitrypsin deficiency (AATD) due to PiZZ genotype.
started
Mar 17, 2026
primary completion
Nov 1, 2028
completion
Jan 1, 2029
last updated
Apr 28, 2026
detailed description
The study is designed to evaluate the safety, tolerability, PK, and PD of AIR-001.
official title
Phase 1, Open-Label, Single Ascending Dose and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered AIR-001 in Adults With AATD Due to PiZZ Genotype
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol